Loading...
Please wait, while we are loading the content...
Similar Documents
Clinical significance and prognostic value of STAT 3 expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy
| Content Provider | Semantic Scholar |
|---|---|
| Author | Sun, Caihong Xie, Wanzhuo Qian, Wenbin Ye, Xiujin |
| Copyright Year | 2016 |
| Abstract | The clinical significance and prognostic value of Signal transducer and activator of transcription 3 (STAT3) were investigated in a cohort (n=52) of patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), by immunohistochemical (IHC) analysis in this study. High STAT3 expression was detected in 65.38% (34/52) cases. Compared with germinal center B-cell (GCB) group, the non-GCB group had significantly higher STAT3 expression rate (82.61% versus 51.72%, P=0.02). Our data also suggest that high STAT3 expression level correlated with poor survival in DLBCL patients with respect to both 5-year OS (72.2% versus 41.2%, P=0.033) and PFS (66.7% versus 32.4%, P=0.023). The results of this study provide evidence for the ongoing researches targeting STAT3 in DLBCL. |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.ijcem.com/files/ijcem0019575.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
